A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin-cisplatin and radiotherapy
Autor: | Pendjer, I., Krejovic, B., Vucicevic, S. |
---|---|
Zdroj: | European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS); January 1997, Vol. 254 Issue: Supplement 1 pS127-S129, 3p |
Abstrakt: | Abstract: Undifferentiated nasopharyngeal carcinoma has been related to the Epstein-Barr virus. These tumors are known to be radiosensitive and chemosensitive. While radiotherapy (RT) allows for a high rate of local control, 80% of all patients die from or with metastatic spread. This study analyzed 61 patients treated with RT alone and 28 treated with zorubicin (ZRB) — cisplatin (CDDP) and RT between 1977 and 1990. All patients treated with RT received 60–74 Gy in 6–7 weeks. Patients treated with combined therapy received ZRB 250 mg/m2 on the 1st day and CDDP 30 mg/m2 from the 2nd to 5th day. The interval between cycles was 4 weeks. Following treatment with chemotherapy patients were then given RT. The 5-year survival rate was 20% for patients with T1 and T2 tumors when treated with RT alone and 54% when treated with chemotherapy (CT). This was 25% for T3 and T41esions with RT only and 27% for RT with CT. Survival of patients with NO and N1 lesions was 41% after RT and 60% after RT with CT. This decreased to 10% for N2 and N3 lesions treated with RT and 30% with RT and CT. |
Databáze: | Supplemental Index |
Externí odkaz: |
načítá se...